Sermorelin vs Tesamorelin: How the Two GHRH Peptides Compare

The short answer: sermorelin and tesamorelin both copy growth hormone-releasing hormone (GHRH), the signal that tells your pituitary to release its own growth hormone. The big difference is status. Tesamorelin is the active ingredient in Egrifta, an FDA-approved prescription drug with one narrow use. Sermorelin was approved as Geref, but the maker stopped selling it in 2008, and today it's only available compounded.

The evidence gap is just as wide. Tesamorelin's label rests on two large trials of more than 400 people each. Sermorelin's studies in older adults are small, short and mostly from the 1990s.

Status as of October 24, 2026: tesamorelin (Egrifta WR) is FDA-approved only to reduce excess belly fat in adults with HIV and lipodystrophy. Sermorelin has no FDA-approved product on the market. FDA found in 2013 that Geref wasn't withdrawn for safety or effectiveness reasons. This post describes what the labels, FDA records and studies say. It isn't medical advice. Ask your doctor whether either one fits you.

Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.

Same target, different paperwork. Here's the side-by-side from the FDA records, the Egrifta label and the published studies.

Sources: FDA Federal Register notice, March 4, 2013, Geref label via RxList, Egrifta WR label, rev. 3/2025, Drugs.com price guide (read October 24, 2026).

Both are GHRH analogs. They bind the GHRH receptor on the pituitary, and the pituitary releases more of your own growth hormone. Neither one is growth hormone.

The Egrifta label explains the system: GHRH "acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone." It also says tesamorelin "binds and stimulates human GRF receptors with similar potency as the endogenous GRF" (Egrifta WR label). GRF and GHRH are two names for the same hormone.

Sermorelin is the front 29 amino acids of that hormone. Tesamorelin keeps all 44 and adds a small fatty chain at the front end.

One thing many comparison pages get wrong: they call tesamorelin the "longer-acting" one. On paper, the two clear the blood about equally fast. The old Geref label gives sermorelin a half-life of 11 to 12 minutes (RxList), and the Egrifta WR label gives tesamorelin 11 minutes.

Because they pull the same lever, they're usually discussed as alternatives, not partners. How GHRH drugs differ from the ghrelin-side peptides like ipamorelin is covered in your GH stack, explained honestly.

Not anymore. Geref was FDA-approved as an injection, first in 1990 as a test of pituitary function and then in 1997 to treat growth failure in children with idiopathic growth hormone deficiency (Federal Register).

EMD Serono told FDA in 2008 that it was discontinuing both products. FDA withdrew the approvals at the company's request, effective June 18, 2009. The Endocrine Society's guideline on adult growth hormone deficiency noted the gap plainly: "The production of the only commercially available formulation of GHRH in the United States was discontinued in 2008" (Molitch et al., 2011).

Then in 2013, responding to a citizen petition, FDA published a formal finding that Geref was "not withdrawn for reasons of safety or effectiveness." That cleared the way for a generic version. As of October 24, 2026, FDA's drug database lists only the two discontinued Geref applications for sermorelin. No generic has ever been approved.

So sermorelin is a drug FDA once approved, didn't pull for safety, and that nobody sells as an approved product today.

It's sold by prescription through compounding pharmacies. What FDA hasn't done is publish a sermorelin-specific answer on how that fits the compounding rules.

Here's what the FDA records show:

The legal question pharmacies argue about is whether a drug that was approved and then discontinued still counts as a "component of an FDA-approved drug" under the federal compounding law. Clinic and vendor pages answer it both ways. I couldn't find FDA answering it for sermorelin.

Sermorelin is also sold online as "research use only." FDA's August 2026 warning letters to online peptide sellers said that label "did not outweigh evidence that the products were intended for human use" (Holland & Knight).

Yes, for one use. FDA approved Egrifta on November 10, 2010 (Drugs@FDA). The current version, Egrifta WR, is indicated "for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy" (Egrifta WR label).

The label also says what it's not for. It's "not indicated for weight loss management as it has a weight neutral effect," and its long-term heart safety "has not been established."

The full rundown on tesamorelin, from the trials to the legal questions, is in what tesamorelin is and what it isn't.

Small, short studies found that sermorelin-type GHRH raised growth hormone in older adults. Changes in the body were modest and inconsistent. None of these studies is newer than 1997.

That's the core of the over-50 evidence. The largest group is 19 people, the longest run is 16 weeks, and no study measured long-term safety or outcomes like falls, fractures or disease. The Endocrine Society's guideline notes that growth hormone "has not been approved by the Food and Drug Administration as an antiaging treatment" (Molitch et al., 2011).

Tesamorelin over 50, for comparison. The best trial in older adults without HIV gave tesamorelin or placebo to 152 adults aged 55 to 87 for 20 weeks. The tesamorelin group did better on thinking tests, mainly executive function. IGF-1 rose 117% but stayed in the normal range, and body fat fell 7.4%. Mild side effects were reported by 68% on tesamorelin vs 36% on placebo (Baker et al., 2012). That's one trial, and the drug maker supplied the drug.

Very little. The only sermorelin-family trial I found that reported women separately is the 1997 study above. Its 10 women, aged 55 to 71, had higher IGF-1 and thicker skin, but no change in lean mass, insulin sensitivity, well-being or libido. The authors concluded the effects favored men "more than women" (Khorram et al., 1997).

I found no trial of sermorelin or tesamorelin in menopausal women specifically, and no data on using either alongside hormone therapy. Tesamorelin's two label trials were about 85% men. If menopause is your reason for asking, that's a gap worth raising with your doctor.

For sermorelin, the main side effect in the old Geref trials was a reaction at the injection site. Tesamorelin's label has a longer list, because it was studied far more.

Sermorelin. The Geref label says the most common treatment-related event, "occurring in about 1 patient in 6," was a local injection reaction with pain, swelling or redness. Three of 350 trial patients stopped for that reason. Headache, flushing, dizziness and hives each occurred in less than 1%. "A large proportion of patients" developed antibodies to the drug (RxList). Those trials were in children. In the older-adult studies, the only side effect reported in the 16-week study was a temporary rise in blood fats (Khorram et al., 1997).

Tesamorelin. Over 26 weeks in the label trials (Egrifta WR label):

The label also says not to use it with active cancer or during pregnancy, and it has "no information" on use in people over 65.

None of this transfers neatly to compounded products. Compounded sermorelin isn't the Geref that was tested, and FDA says it "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" (FDA).

Compounded sermorelin is listed at roughly $100 to $400 a month. Brand tesamorelin is about $11,000 for a 28-day kit, cash.

Sermorelin. Price guides from clinics and directories list telehealth programs from about $100 to $200 a month and local clinics at $200 to $400 a month, plus consult and lab fees. Several of those pages earn commissions from the programs they list, and none says how its numbers were gathered. Insurance rarely pays, because there's no FDA-approved sermorelin product to put on a formulary.

Tesamorelin. Drugs.com lists one Egrifta WR kit at "around $11,030" for cash-paying customers (Drugs.com, read October 24, 2026). Per the label, a kit holds four vials and a 28-day supply of injection supplies. Other price sites quote very different numbers, so check your pharmacy. The maker runs a co-pay program for eligible commercially insured patients.

CJC-1295 is a third GHRH analog, built to last much longer. It has never been FDA-approved, and FDA has flagged safety concerns.

In two placebo-controlled trials of healthy adults aged 21 to 61, lasting 28 and 49 days, one injection of CJC-1295 raised growth hormone 2- to 10-fold for 6 days or more, and its half-life was 5.8 to 8.1 days (Teichman et al., 2006). Compare that with about 11 minutes for sermorelin and tesamorelin. The authors, tied to the developer, reported no serious adverse reactions.

FDA's view is less relaxed. Its compounding safety page says FDA "has identified serious adverse events associated with CJC-1295 including increased heart rate" and a "systemic vasodilatory reaction," notes a possible immune reaction risk, and says "available clinical data are limited" (FDA, April 2026).

There's no sermorelin sleep trial I could find. Sleep claims mostly borrow from research on natural GHRH, and the closest sermorelin-type study found no change.

Growth hormone is released largely during deep sleep, which is why the two get linked (why GH is more than a size signal). In one sleep-lab study, natural GHRH sprayed in the nose before bed increased deep and REM sleep in 12 young and 11 older men, over a single night (Perras et al., 1999). That wasn't sermorelin, and it wasn't an injection.

The one longer study of a sermorelin-type peptide in older adults asked about sleep directly. After 16 weeks, "sleep quality was unaffected in both genders" (Khorram et al., 1997).

Neither, in the way the question usually means. They've never been compared head to head, and they're not in the same place legally or scientifically.

Tesamorelin is the one with an FDA label, large trials and a clear list of risks, but that label covers one condition in adults with HIV. Its trial results also faded when people stopped: in the label's extension phase, belly fat rose 16% to 22% within 26 weeks of switching to placebo. Sermorelin is the one with a history of approval and no safety withdrawal, but its evidence in older adults is a handful of small studies, and today's supply is compounded.

If you're over 50 and asking about either, the useful questions for your doctor are what you're trying to fix, how it would be measured, and how IGF-1 and blood sugar would be watched.

Want the one-page version of what's approved, what's legal and what's actually been tested? Get the free BHN cheat sheet.